Dupixent approved to treat bullous pemphigoid
Dupixent (dupilumab) has been approved by the FDA for the treatment of adult patients with bullous pemphigoid.| Drug Discovery and Development
By Brian Buntz | June 25, 2025| Drug Discovery and Development
Dupixent (dupilumab) has been approved by the FDA for the treatment of adult patients with bullous pemphigoid.| Drug Discovery and Development
The phase 4 EVEREST study showed that Dupixent demonstrated superiority over Xolair in adults with chronic rhinosinusitis.| Drug Discovery and Development
By Julia Rock-Torcivia | June 20, 2025| Drug Discovery and Development
Sanofi and Regeneron have announced that the monoclonal antibody outperformed Xolair (omalizumab) on all primary and secondary efficacy endpoints in a phase 4 study focused on patients with chronic rhinosinusitis.| Drug Discovery and Development
